A CAR T-cell therapy called CART-ddBCMA that targets the protein BCMA — produced at high levels in myeloma cells — safely led to lasting responses in relapsed and refractory multiple myeloma (RRMM) patients, a Phase 1 study showed. Given the small study size, further trials in larger groups of patients are needed to confirm these findings. But, according to researchers, the trial — “designed to evaluate the initial safety of CART-ddBCMA administration” — was the…
May 24, 2022May 24, 2022